Induction of premature senescence by Hsp90 inhibition in small cell lung cancer

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Restall, Ian J ^a,b   Lorimer, Ian A J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE H2AX; PROTEIN P21; RADICICOL; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM;

ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PROTEIN EXPRESSION; SENESCENCE; APOPTOSIS; CELL AGING; DRUG ANTAGONISM; DRUG EFFECT; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; CARCINOMA, SMALL CELL; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS;

EID: 77956193668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011076     Document Type: Article

References (52)

1. Wandinger SK, Richter K, Buchner J (2008) The Hsp90 chaperone machinery. J Biol Chem 283: 18473-18477.
2. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271-294.
3. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410: 439-453.
4. Xu Y, Singer MA, Lindquist S (1999) Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci U S A 96: 109-114.
5. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA (2003) Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278: 5292-5299.
6. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, et al. (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589-596.
7. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A highaffinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
8. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, et al. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276: 3702-3708.
9. Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, et al. (1999) Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol Endocrinol 13: 1435-1448.
10. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, et al. (2000) The hsp90- related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275: 3305-3312.
11. Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol 8: 370-374.
12. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, et al. (2005) Phase I trial of 17- allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087.
13. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, et al. (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-1893.
14. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161.
15. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I doseescalation study. J Clin Oncol 25: 5410-5417.
16. Sher T, Dy GK, Adjei AA (2008) Small cell lung cancer. Mayo Clin Proc 83: 355-367.
17. Cook RM, Miller YE, Bunn PA, Jr. (1993) Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 17: 69-141.
18. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, et al. (2007) Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 3: 498-507.
19. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, et al. (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6: 3312-3318.
20. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DTDiaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940-1949.
21. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, et al. (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:- quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65: 10006-10015.
22. Smith PJ, Wiltshire M, Chin SF, Rabbitts P, Soues S (1999) Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells. Int J Radiat Biol 75: 1137-1147.
23. Funayama R, Ishikawa F (2007) Cellular senescence and chromatin structure. Chromosoma 116: 431-440.
24. Narita M, Nunez S, Heard E, Narita M, Lin AW, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716.
25. d'Adda dF, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198.
26. Passos JF, Nelson G, Wang C, Richter T, Simillion C, et al. (2010) Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol.Syst Biol 6: 347.
27. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, et al. (1999) p21Waf1/ Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18: 2789-2797.
28. Srethapakdi M, Liu F, Tavorath R, Rosen N (2000) Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60: 3940-3946.
29. Kim HR, Lee CH, Choi YH, Kang HS, Kim HD (1999) Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells. IUBMB Life 48: 425-428.
30. Stepanova L, Leng X, Parker SB, Harper JW (1996) Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10: 1491-1502.
31. Munoz MJ, Jimenez J (1999) Genetic interactions between Hsp90 and the Cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet 261: 242-250.
32. de Carcer G (2004) Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 64: 5106-5112.
33. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, et al. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110: 2641-2649.
34. Soengas MS (2008) Cancer: Ins and outs of tumour control. Nature 454: 586-587.
35. Campisi J, d'Adda dF (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
36. Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23: 2919-2933.
37. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, et al. (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59: 3761-3767.
38. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346.
39. Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim Biophys Acta 1775: 5-20.
40. Gewirtz DA, Holt SE, Elmore LW (2008) Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem.Pharmacol 76: 947-957.
41. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, et al. (2005) Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 8: 19-30.
42. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, et al. (2006) Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol, 8: 1053-1063.
43. Keppler BR, Grady AT, Jarstfer MB (2006) The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J Biol Chem 281: 19840-19848.
44. Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T (2007) Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 109: 5016-5026.
45. Lee BY, Han JA, Im JS, Morrone A, Johung K, et al. (2006) Senescenceassociated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5: 187-195.
46. Erlichman C (2009) Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs, 18: 861-868.
47. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, et al. (2009) Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 69: 1966-1975.
48. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, et al. (2002) Inhibition of p21- mediated ROS accumulation can rescue p21-induced senescence. EMBO J 21: 2180-2188.
49. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC (2007) Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131: 257-270.
50. Kang BH, Plescia J, Song HY, Meli M, Colombo G, et al. (2009) Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 119: 454-464.
51. Ostrovsky O, Ahmed NT, Argon Y (2009) The chaperone activity of GRP94 toward insulin-like growth factor II is necessary for the stress response to serum deprivation. Mol Biol Cell 20: 1855-1864.
52. Baldwin RM, Garratt-Lalonde M, Parolin DA, Krzyzanowski PM, Andrade MA, et al. (2006) Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene 25: 2909-2919.